Financial Performance - The company's operating revenue for Q3 2023 was ¥2,717,355,073.30, a decrease of 18.45% compared to the same period last year[4]. - Net profit attributable to shareholders for the same period was ¥218,980,497.85, an increase of 8.66% year-over-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 28.96% to ¥207,955,269.48[4]. - The basic earnings per share for Q3 2023 was ¥0.1648, down 16.05% from the previous year[4]. - Total operating revenue for the first three quarters of 2023 was ¥9,161,881,346.47, a decrease of 5.73% compared to ¥9,719,160,020.44 in the same period of 2022[22]. - Net profit for the first three quarters of 2023 reached CNY 797.50 million, a 32.06% increase from CNY 604.17 million in the same period of 2022[53]. - The total profit for the first three quarters of 2023 was CNY 925.61 million, representing a 24.48% increase compared to CNY 743.66 million in 2022[53]. - The net profit for the first three quarters of 2023 was CNY 315,923,881.36, down 48.9% from CNY 616,568,798.23 in the first three quarters of 2022[63]. Assets and Liabilities - The total assets at the end of the reporting period were ¥19,051,306,528.38, a decrease of 2.95% compared to the end of the previous year[5]. - The total liabilities decreased to ¥3,533,047,488.76 as of September 30, 2023, compared to ¥4,195,505,744.49 at the end of 2022, a reduction of 15.77%[22]. - The total liabilities decreased to CNY 2,097,629,624.64 as of September 30, 2023, from CNY 5,216,162,695.77 at the end of 2022, representing a reduction of 59.9%[61]. - The company's total equity increased to CNY 10,816,432,353.58 as of September 30, 2023, from CNY 9,109,774,548.12 at the end of 2022, marking an increase of 18.7%[61]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,446,542,946.66, down 26.41% year-over-year[4]. - Net cash flow from operating activities for the first three quarters of 2023 was ¥102,707,949.72, a decrease of 87.87% compared to ¥846,998,456.75 in the same period of 2022[36]. - The company's cash inflow from operating activities for the first three quarters of 2023 was CNY 1,179,762,732.67, compared to CNY 1,354,620,227.41 in the same period of 2022, indicating a decline of 12.9%[70]. - The cash balance at the end of the period was ¥2,357,754,769.34, compared to ¥1,821,616,111.10 at the end of 2022, indicating an increase of 29.43%[36]. Expenses - The company managed to reduce its total expenses by 20.04% year-to-date, enhancing its profitability[12]. - Total operating costs for the first three quarters of 2023 were ¥8,245,179,979.15, down from ¥9,013,362,094.64 in 2022, reflecting a reduction of 8.52%[22]. - Sales expenses decreased to CNY 1.67 billion, down 23.52% from CNY 2.19 billion year-over-year[53]. - Research and development expenses increased to CNY 376.89 million, up 4.49% from CNY 360.09 million in the previous year[53]. - The company's financial expenses improved, with interest expenses decreasing to CNY 48.06 million from CNY 84.54 million in the previous year[53]. - The financial expenses decreased significantly to CNY 16,810,644.12 in the first three quarters of 2023, down from CNY 60,089,509.39 in the same period of 2022, a reduction of 72.0%[63]. Investments and Future Plans - The company received government subsidies amounting to ¥20,032,027.34 during the reporting period[5]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[57].
国药现代(600420) - 2023 Q3 - 季度财报